2026-04-13T16:55:49Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/74052025-10-24T10:36:18Zcom_2072_378070com_2072_378040col_2072_378092

Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders Kuwana, Masataka Gil Vila, Albert Selva O'Callaghan, Albert Institut Català de la Salut [Kuwana M] Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine; Scleroderma/Myositis Center of Excellence (SMCE) Nippon Medical School Hospital, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, Japan. [Gil-Vila A, Selva-O'Callaghan A] Unitat de Malalties Autoimmunes Sistèmiques, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain Vall d'Hebron Barcelona Hospital Campus Pulmons - Malalties - Complicacions Malalties autoimmunitàries Autoanticossos DISEASES::Respiratory Tract Diseases::Lung Diseases::Lung Diseases, Interstitial Other subheadings::Other subheadings::Other subheadings::/complications DISEASES::Immune System Diseases::Autoimmune Diseases CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Autoantibodies ENFERMEDADES::enfermedades respiratorias::enfermedades pulmonares::enfermedades pulmonares intersticiales Otros calificadores::Otros calificadores::Otros calificadores::/complicaciones ENFERMEDADES::enfermedades del sistema inmune::enfermedades autoinmunes COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::autoanticuerpos Autoanticuerpos; Trastornos reumáticos autoinmunes; Enfermedad pulmonar intersticial Autoanticossos; Trastorns reumàtics autoimmunes; Malaltia pulmonar intersticial Autoantibodies; Autoimmune rheumatic disorders; Interstitial lung disease Interstitial lung disease (ILD) has been recognized as a frequent manifestation associated with a substantial morbidity and mortality burden in patients with autoimmune rheumatic disorders. Serum autoantibodies are considered good biomarkers for identifying several subsets or specific phenotypes of ILD involvement in these patients. This review features the role of several autoantibodies as a diagnostic and prognostic biomarker linked to the presence ILD and specific ILD phenotypes in autoimmune rheumatic disorders. The case of the diverse antisynthetase antibodies in the antisynthease syndrome or the anti-melanoma differentiation-associated 5 protein (MDA5) antibodies as a marker of a severe condition such as rapidly progressive ILD in patients with clinically amyopathic dermatomyositis are some of the associations herein reported in the group of myositis spectrum disorders. Specific autoantibodies such as the well-known anti-topoisomerase I (anti-Scl70) or the anti-Th/To, anti-U11/U12 ribonucleoprotein, and anti-eukaryotic initiation factor 2B (eIF2B) antibodies seems to be specifically linked to ILD in patients with systemic sclerosis. Overlap syndromes between systemic sclerosis and myositis, also have good ILD biomarkers, which are the anti-PM/Scl and anti-Ku autoantibodies. Lastly, other not so often reported disorders as being associated with ILD but recently most recognized as is the case of rheumatoid arthritis associated ILD or entities herein included in the miscellaneous disorders section, which include anti-neutrophil cytoplasmic antibody-associated interstitial lung disease, Sjögren’s syndrome or the mixed connective tissue disease, are also discussed. The authors received no financial support for the research, authorship, and/or publication of this article. 2022-04-25T14:50:54Z 2022-04-25T14:50:54Z 2021-01-01 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Kuwana M, Gil-Vila A, Selva-O’Callaghan A. Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders. Ther Adv Musculoskelet Dis. 2021 Jan 1;13:1–17. 1759-7218 https://hdl.handle.net/11351/7405 10.1177/1759720X211032457 34377160 000688106300001 http://hdl.handle.net/11351/7405 eng Therapeutic Advances in Musculoskeletal Disease;13 https://doi.org/10.1177/1759720X211032457 Attribution-NonCommercial 4.0 International http://creativecommons.org/licenses/by-nc/4.0/ info:eu-repo/semantics/openAccess application/pdf SAGE Publications Scientia